felodipine has been researched along with Chronic Disease in 13 studies
Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.
felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The echocardiographic substudy of the Vasodilator-Heart Failure Trial III (V-HeFT III) aimed to determine if felodipine treatment in patients with heart failure who were taking an angiotensin-converting enzyme inhibitor had a favorable effect on left ventricular (LV) structure and function." | 9.09 | Felodipine improves left ventricular emptying in patients with chronic heart failure: V-HeFT III echocardiographic substudy of multicenter reproducibility and detecting functional change. ( Baruch, L; Cohen, IS; Cohn, JN; Deedwania, P; Germanson, T; Lopez, B; Perry, G; Taylor, WR; Wong, M, 2000) |
| "Twenty patients on conventional therapy for severe congestive heart failure (CHF) were randomly assigned to adjunctive treatment with felodipine (n = 10) or placebo (n = 10) and followed over a 6-month period." | 9.06 | Long-term clinical, hemodynamic, angiographic, and neurohumoral responses to vasodilation with felodipine in patients with chronic congestive heart failure. ( Amtorp, O; Kassis, E, 1990) |
| "Previous open studies have suggested that felodipine, a selective calcium antagonist and vasodilator, may be useful in the treatment of heart failure." | 9.06 | Felodipine in patients with chronic heart failure: discrepant haemodynamic and clinical effects. ( Littler, WA; Murray, RG; Tan, LB, 1987) |
| "In order to assess the effect of felodipine, a new calcium antagonist with vascular selectivity, on regional blood flow distribution at rest in chronic congestive heart failure, ten patients were studied during an acute test." | 7.67 | Felodipine in severe chronic congestive heart failure: acute effects on central hemodynamics and regional blood flow distribution. ( Binetti, G; Cervi, V; Ferretti, RM; Magnani, B; Rubino, I; Spadoni, R; Varani, E, 1989) |
| "Felodipine is a second-generation dihydropyridine calcium antagonist with a high degree of vascular selectivity which, in the doses used in this study, exerts its systemic arterial effect by decreasing peripheral vascular resistance without producing negative inotropic effects." | 6.68 | Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators. ( Boden, WE; Carson, PE; Cohn, JN; Conrad, CH; Syat, D; Ziesche, S, 1996) |
| " Four hours after dosing with both felodipine doses, only 5 patients discontinued the exercise test because of greater than 2 mm of ST-segment depression, whereas 10 continued until exhaustion (p less than 0." | 6.67 | Twenty-four-hour activity of felodipine extended release in chronic stable angina pectoris. ( Alberti, D; Di Bello, V; Giusti, C; Santoro, G; Savonitto, S, 1991) |
| "The echocardiographic substudy of the Vasodilator-Heart Failure Trial III (V-HeFT III) aimed to determine if felodipine treatment in patients with heart failure who were taking an angiotensin-converting enzyme inhibitor had a favorable effect on left ventricular (LV) structure and function." | 5.09 | Felodipine improves left ventricular emptying in patients with chronic heart failure: V-HeFT III echocardiographic substudy of multicenter reproducibility and detecting functional change. ( Baruch, L; Cohen, IS; Cohn, JN; Deedwania, P; Germanson, T; Lopez, B; Perry, G; Taylor, WR; Wong, M, 2000) |
| "Twenty patients on conventional therapy for severe congestive heart failure (CHF) were randomly assigned to adjunctive treatment with felodipine (n = 10) or placebo (n = 10) and followed over a 6-month period." | 5.06 | Long-term clinical, hemodynamic, angiographic, and neurohumoral responses to vasodilation with felodipine in patients with chronic congestive heart failure. ( Amtorp, O; Kassis, E, 1990) |
| "Previous open studies have suggested that felodipine, a selective calcium antagonist and vasodilator, may be useful in the treatment of heart failure." | 5.06 | Felodipine in patients with chronic heart failure: discrepant haemodynamic and clinical effects. ( Littler, WA; Murray, RG; Tan, LB, 1987) |
| "In order to assess the effect of felodipine, a new calcium antagonist with vascular selectivity, on regional blood flow distribution at rest in chronic congestive heart failure, ten patients were studied during an acute test." | 3.67 | Felodipine in severe chronic congestive heart failure: acute effects on central hemodynamics and regional blood flow distribution. ( Binetti, G; Cervi, V; Ferretti, RM; Magnani, B; Rubino, I; Spadoni, R; Varani, E, 1989) |
| "In chronic asymptomatic aortic regurgitation, felodipine causes beneficial hemodynamic effects that may postpone the need for valve replacement." | 2.69 | Vasodilatation with felodipine in chronic asymptomatic aortic regurgitation. ( Aldershvile, J; Hildebrandt, P; Kelbaek, H; Ståhlberg, F; Søndergaard, L; Thomsen, C, 2000) |
| "Felodipine is a second-generation dihydropyridine calcium antagonist with a high degree of vascular selectivity which, in the doses used in this study, exerts its systemic arterial effect by decreasing peripheral vascular resistance without producing negative inotropic effects." | 2.68 | Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators. ( Boden, WE; Carson, PE; Cohn, JN; Conrad, CH; Syat, D; Ziesche, S, 1996) |
| " Four hours after dosing with both felodipine doses, only 5 patients discontinued the exercise test because of greater than 2 mm of ST-segment depression, whereas 10 continued until exhaustion (p less than 0." | 2.67 | Twenty-four-hour activity of felodipine extended release in chronic stable angina pectoris. ( Alberti, D; Di Bello, V; Giusti, C; Santoro, G; Savonitto, S, 1991) |
| "In conclusion, in patients with chronic cardiac failure, treatment with a calcium channel blocker produced sustained haemodynamic improvement, particularly on exercise, and combination with nitrate produced further benefit." | 2.66 | Calcium channel blocker and isosorbide 5-mononitrate in the management of chronic cardiac failure. ( Hutton, I; Martin, W; McGhie, AI; Tweddel, AC, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (30.77) | 18.7374 |
| 1990's | 5 (38.46) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fomin, VV | 1 |
| Drapkina, OM | 1 |
| Ashikhmin, IaI | 1 |
| Boden, WE | 1 |
| Ziesche, S | 1 |
| Carson, PE | 1 |
| Conrad, CH | 1 |
| Syat, D | 1 |
| Cohn, JN | 2 |
| Valle, M | 1 |
| Esteban, M | 1 |
| Rodríguez-Sasiaín, JM | 1 |
| Calvo, R | 1 |
| Aguirre, C | 1 |
| Søndergaard, L | 1 |
| Aldershvile, J | 1 |
| Hildebrandt, P | 1 |
| Kelbaek, H | 1 |
| Ståhlberg, F | 1 |
| Thomsen, C | 1 |
| Wong, M | 1 |
| Germanson, T | 1 |
| Taylor, WR | 1 |
| Cohen, IS | 1 |
| Perry, G | 1 |
| Baruch, L | 1 |
| Deedwania, P | 1 |
| Lopez, B | 1 |
| Terland, O | 1 |
| Kassis, E | 2 |
| Amtorp, O | 2 |
| Santoro, G | 1 |
| Savonitto, S | 1 |
| Di Bello, V | 1 |
| Alberti, D | 1 |
| Giusti, C | 1 |
| Binetti, G | 1 |
| Rubino, I | 1 |
| Varani, E | 1 |
| Spadoni, R | 1 |
| Ferretti, RM | 1 |
| Cervi, V | 1 |
| Magnani, B | 1 |
| Tan, LB | 1 |
| Murray, RG | 1 |
| Littler, WA | 1 |
| Waldorff, S | 1 |
| Hutton, I | 1 |
| McGhie, AI | 1 |
| Martin, W | 1 |
| Tweddel, AC | 1 |
1 review available for felodipine and Chronic Disease
| Article | Year |
|---|---|
[Calcium antagonists: on the way to expanding the indications].
Topics: Atherosclerosis; Calcium; Calcium Channel Blockers; Chronic Disease; Felodipine; Humans; Hypertensio | 2010 |
9 trials available for felodipine and Chronic Disease
| Article | Year |
|---|---|
[Calcium channels blocker felodipin in the treatment of patients with arterial hypertension and chronic cardial failure with preserved cardiac output].
Topics: Blood Pressure; Calcium Channel Blockers; Cardiac Output; Chronic Disease; Diagnosis, Differential; | 2011 |
Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators.
Topics: Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiotonic Agents; Chronic Dise | 1996 |
Vasodilatation with felodipine in chronic asymptomatic aortic regurgitation.
Topics: Adult; Aged; Aortic Valve Insufficiency; Chronic Disease; Double-Blind Method; Felodipine; Female; H | 2000 |
Felodipine improves left ventricular emptying in patients with chronic heart failure: V-HeFT III echocardiographic substudy of multicenter reproducibility and detecting functional change.
Topics: Calcium Channel Blockers; Chronic Disease; Echocardiography, Doppler, Color; Felodipine; Heart Failu | 2000 |
Long-term clinical, hemodynamic, angiographic, and neurohumoral responses to vasodilation with felodipine in patients with chronic congestive heart failure.
Topics: Adult; Aged; Angiocardiography; Blood Cell Count; Catecholamines; Chronic Disease; Epinephrine; Felo | 1990 |
Twenty-four-hour activity of felodipine extended release in chronic stable angina pectoris.
Topics: Aged; Angina Pectoris; Chronic Disease; Delayed-Action Preparations; Double-Blind Method; Drug Admin | 1991 |
Felodipine in patients with chronic heart failure: discrepant haemodynamic and clinical effects.
Topics: Aged; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Echocardiography; Exercise Tes | 1987 |
Haemodynamic effects of felodipine during supine resting and exercising states and orthostatic tilt in patients with chronic congestive heart failure.
Topics: Antihypertensive Agents; Chronic Disease; Felodipine; Heart Failure; Hemodynamics; Humans; Nitrendip | 1987 |
Calcium channel blocker and isosorbide 5-mononitrate in the management of chronic cardiac failure.
Topics: Chronic Disease; Coronary Disease; Drug Therapy, Combination; Exercise Test; Felodipine; Heart Failu | 1987 |
3 other studies available for felodipine and Chronic Disease
| Article | Year |
|---|---|
Characteristics of serum protein binding of felodipine.
Topics: Adult; Age Factors; Aged; Antihypertensive Agents; Blood Proteins; Calcium Channel Blockers; Chronic | 1996 |
Treatment of chronic heart failure.
Topics: Chronic Disease; Felodipine; Heart Failure; Humans | 1992 |
Felodipine in severe chronic congestive heart failure: acute effects on central hemodynamics and regional blood flow distribution.
Topics: Adult; Aged; Blood Pressure; Chronic Disease; Felodipine; Heart Failure; Heart Rate; Hemodynamics; H | 1989 |